

KATE SAYLOR, Ph.D.

Email: ksaylor@geisinger.edu • Phone: 530-400-8735

INTERESTS

I use quantitative data analysis, cost-effectiveness simulation modeling, and philosophical analysis to investigate health disparities, the distribution of benefits from genetics research and medicine, and the normative issues in quantitative methods. My research draws upon my expertise in molecular biology and federal science policy.

FACULTY APPOINTMENTS

Assistant Professor of Bioethics, and Health & Research Policy September 2024 – present
Department of Bioethics and Decision Sciences, Geisinger, Danville, PA.

POSTDOCTORAL RESEARCH EXPERIENCE

Postdoctoral Research Fellow August 2021 – August 2024
Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia, PA.

- **Research project:** Cost-Effectiveness of *BRCA1/BRCA2* genetic testing for high-risk, low-income, uninsured women
- **Primary mentor:** Steven Joffe, M.D., M.P.H., University of Pennsylvania
- **Secondary mentor:** David Kim, Ph.D., University of Chicago

EDUCATION

Ph.D. in Public Policy August 2016 – August 2021
University of North Carolina, Chapel Hill, NC.

- **Specialization:** Bioethics, health policy, and healthcare priority-setting
- **Dissertation title:** “*Fairness-informed cost-utility analysis methods to assess the potential of population genetic screening to improve health and reduce disparities*”
<https://www.proquest.com/docview/2563500900?pq-origsite=gscholar&fromopenview=true>
- **Ph.D. advisor:** Douglas MacKay, Ph.D.

M.S. in Neuroscience September 2006 – June 2010
Oregon Health & Sciences University, Portland, OR.

- **Master’s thesis title:** “*Developmental Regulation of Fascin and Plastin Actin Crosslinkers in the Chicken Basilar Papilla*”
- **Advisor:** Peter Barr-Gillespie, Ph.D.

B.A. in Biology/Neurobiology (high honors) September 2001 – May 2005
Macalester College, St. Paul, MN.

PROFESSIONAL EXPERIENCE

Science policy

Special Assistant to the Associate Director for Science Policy **June 2015 – June 2016**

Office of the Director, National Institutes of Health, Bethesda, MD.

- Policy development for the All of Us research program; investigation and briefing senior NIH officials, FDA liaisons, and congressional staff; bioethics expert on policies related to data sharing, informed consent, and genomics research.
- Staffed the committee report “Reducing risk and promoting patient safety for NIH intramural clinical research: The Clinical Center Working Group Report to the Advisory Committee to the Director, NIH.” *National Institutes of Health*. (2016).
https://acd.od.nih.gov/documents/reports/Red_Team_final_report_4262016.pdf

Health Policy Analyst **August 2013 – June 2015**

National Human Genome Research Institute, National Institutes of Health.

- Development, revision, and implementation of policies for human subjects research, standard of care research, and genomic data sharing; revising and updating an online informed consent resource; reporting on the research portfolio.

Special Assistant to the Deputy Director **August 2012 – August 2013**

National Institute of Neurological Disorders and Stroke, National Institutes of Health.

- Strategic planning and implementation of plans for stroke research; rapid turnaround state of the science reviews for institute leadership; editorial support and scientific writing for reports on traumatic brain injury, stroke related to blood pressure guidelines, and autism.

Presidential Management Fellow **August 2010 – August 2012**

National Institutes of Health, Bethesda, MD.

Rotations, 3-4 months each:

- Department of Bioethics, Clinical Center
- Office of Science Policy Analysis, Office of the Director
- Science Policy and Planning Branch, National Institute on Deafness and Other Communication Disorders
- Office of Science Policy and Planning, National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Division of Cancer Treatment and Diagnosis, National Cancer Institute
- Financial Management Branch, National Institute of Dental and Craniofacial Research
- *EXTERNAL ROTATION*: Scientific Responsibility, Human Rights and Law Program, American Association for the Advancement of Science (AAAS), Washington, DC.

Mirzayan Science and Technology Policy Fellow **January 2009 – April 2009**

National Academy of Sciences. Board on Life Sciences, Washington, DC.

- Staffed the committee report “A New Biology for the 21st Century: Ensuring the United States Leads the Coming Biology Revolution.” *National Academies Press*. (2009).
<https://pubmed.ncbi.nlm.nih.gov/20662113/>

Biomedical research (cellular and molecular neuroscience)

Graduate Research Assistant

September 2006 – June 2010

Oregon Health & Sciences University, Portland, OR.

- Developmental, cellular, and molecular biology, western and northern blots, quantitative real-time PCR, micro-dissection, embryonic mouse and chicken surgical techniques for microscope-guided gene transfection, confocal microscopy, electrophysiology.
- Project management, data analysis, scientific writing, scientific presentations.

Post-baccalaureate Research Fellow

July 2005 – July 2006

National Institute on Deafness and Other Communication Disorders, NIH, Rockville, MD.

- Developmental, cellular, and molecular biology, micro-dissection, tissue culture, gene transfection with viral vectors and gene gun, confocal microscopy.

Summer Student

May 2003 – August 2003

The Jackson Laboratory, Bar Harbor, ME.

- Genetic mapping, auditory brainstem response assessment in mice, behavioral testing of mouse vestibular function, micro-dissection, light microscopy.

PUBLICATIONS

Refereed Journal Articles

1. **Saylor KW**, Adams M, Fernandes E, Paraghamian S, Shalowitz D. Predictors of Germline Genetic Testing Referral and Completion in Ovarian Cancer Patients at a Comprehensive Cancer Center. *Gynecologic Oncology* (2024). <https://www.sciencedirect.com/science/article/pii/S0090825824001847>
2. **Saylor KW**, Klein W, Calancie L, Lewis KL, Biesecker LG, Turbit E, Roberts, MC. Genetic testing and other healthcare use by Black and white participants in a genomic sequencing study. *Journal of Public Health Genomics*. (2023). <https://karger.com/phg/article-pdf/doi/10.1159/000533356/3979531/000533356.pdf>
3. **Saylor KW**, Joffe S. Enhancing social value considerations in prioritising publicly funded biomedical research: the vital role of peer review. *Journal of Medical Ethics*. (2023). <https://jme.bmj.com/content/medethics/early/2023/05/24/jme-2022-108883.full.pdf>
4. Allen CG, Olstad D, Kahkoska A, Guan Y, Ramos P, Steinberg J, Staras S, Lumpkins C, Milko L, Turbitt E, Rahm A, **Saylor KW**, Best S, Hatch A., Santangelo I, Roberts MC. Extending an Antiracism Lens to the Implementation of Precision Public Health Interventions. *American Journal of Public Health*. (2023). <https://ajph.aphapublications.org/doi/pdf/10.2105/AJPH.2023.307386>
5. Roberts MC, Foss KS, Henderson GE, Powell SN, **Saylor KW**, Weck KE, Milko LV. Public Interest in Population Genetic Screening for Cancer Risk. *Frontiers in Genetics*. (2022). <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354961/>
6. Johnson KT, **Saylor KW**, Alder IE, Hicklin KT, Berg JS, Hassmiller Lich K. A Systematic Review of the Methodology Quality of Economic Evaluations in Genetic Screening and

- Testing for Monogenic Disorders. *Genetics in Medicine*. (2022).
<https://www.sciencedirect.com/science/article/pii/S1098360021053582>
7. Foss KS, O'Daniel JM, Berg JS, Powell SN, Cadigan RJ, Kuczynski KJ, Milko LV, **Saylor KW**, Roberts MC, Weck K, Henderson GE. The Rise of Population Genomic Screening: Characteristics of current programs and the need for evidence regarding optimal implementation. *Journal of Personalized Medicine*. (2022). <https://www.mdpi.com/2075-4426/12/5/692>
 8. Walker RL, **Saylor KW**, Waltz M, Fisher JA. Translational science: A Survey of US Biomedical Researchers' Perspectives and Practices. *Lab Animal*. (2022).
<https://www.nature.com/articles/s41684-021-00890-0>
 9. Waltz M, **Saylor KW**, Fisher JA, Walker RL. Animal Researchers' Perceptions of the NIH's Sex as a Biological Variable Policy: Results from a US National Survey. *Journal of Women's Health*. doi: 10.1089/jwh.2020.8997 (2021).
<https://www.liebertpub.com/doi/pdf/10.1089/jwh.2020.8997>
 10. Shah SK, Miller FG, Darton TC, Duenas D, Emerson C, Lynch HF, Jamrozik E, Jecker NS, Kamuya D, Kimmelman J, MacKay D, Memoli M, Murphy SC, Palacios R, Richie TL, Roestenberg M, Saxena A, **Saylor KW**, Selgelid MJ, Vaswani V, Rid A. Ethics of controlled human infection to address COVID-19. *Science*. 368(6493):832-4. (2020).
<https://www.science.org/doi/full/10.1126/science.abc1076>
 11. MacKay D, Pitisuttithum P, Jecker N, **Saylor KW**. Selecting Participants Fairly for Controlled Human Infection Studies. *Bioethics*. 34(8):771-784. (2020).
<https://onlinelibrary.wiley.com/doi/pdf/10.1111/bioe.12778>
 12. MacKay D, **Saylor KW**. Four Faces of Fair Subject Selection. *American Journal of Bioethics*. 20(2):5-19. (2020).
<https://www.tandfonline.com/doi/pdf/10.1080/15265161.2019.1701731>
 13. **Saylor KW**, Ekunwe L, Antoine-Lavigne D, Sellers DE, McGraw S, Levy D, Splansky GL, Joffe S. Attitudes towards genetics among participants in the Jackson and Framingham Heart Studies. *Journal of Empirical Research on Human Research Ethics*. 14(3):262-73. (2019).
<https://journals.sagepub.com/doi/pdf/10.1177/1556264619844851>
 14. Juengst ET, Henderson GE, Walker RL, Conley JM, MacKay D, Meagher KM, **Saylor KW**, Waltz M, Kuczynski KJ, Cadigan RJ. Is Enhancement the Price of Prevention in Human Gene Editing? *The CRISPR Journal*. 1(6):351-4. (2018).
<https://www.liebertpub.com/doi/full/10.1089/crispr.2018.0040>
 15. Avenarius MR*, **Saylor KW***, Lundeberg MR*, Wilmarth PA, Shin JB, Spinelli KJ, Pagana JM, Andrade L, Kachar B, Choi D, David LL, Barr-Gillespie PG. Correlation of actin crosslinker and capper expression levels with stereocilia growth phases. *Mol Cell Proteomics*. 13(2):606-20. (*Authors contributed equally) (2013).
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3916657/>
 16. Shin J, Longo-Guess C, Gagnon L, **Saylor KW**, et al. The R109H variant of fascin-2, a developmentally regulated actin crosslinker in hair-cell stereocilia, underlies early-onset hearing loss of DBA/2J mice. *Journal of Neuroscience*. 30(29):9683-9694. (2010).
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2922854/>

17. Powell AE, Shung C-Y, **Saylor KW**, Müllendorf KA, Weiss JB, and Wong MH. Lessons from development: A role for asymmetric stem cell division in cancer. *Stem Cell Research*. 4(1):3-9. (2009). <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2818177/>
18. Gagnon LH, Longo-Guess CM, Berryman M, Shin JB, **Saylor KW**, Yu H, Gillespie PG, and Johnson KR. The chloride intracellular channel protein CLIC5 is expressed at high levels in hair cell stereocilia and is essential for normal inner ear function. *Journal of Neuroscience*. 26(40):10188-98. (2006). <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6674616/>

Book Chapters (peer reviewed)

1. MacKay D, **Saylor KW**. Ethical Aspects of Nudging in Donation Policy, in *Ethical Challenges of Organ Transplantation: Current Debates and International Perspectives*. Columbia University Press, ISBN: 9783839446430 (2021). <https://www.transcript-publishing.com/978-3-8376-4643-6/ethical-challenges-of-organ-transplantation/?number=978-3-8394-4643-0>

Commentaries (not peer reviewed)

1. MacKay D, **Saylor KW**. Was this job market study on social media ethical? *Hastings Bioethics Forum*. (2024). <https://www.thehastingscenter.org/was-this-job-market-study-ethical/>
2. **Saylor KW**, Martschenko DO. Promoting Diagnostic Equity: Specifying Genetic Similarity Rather Than Race or Ethnicity. *Journal of Medical Ethics*. (2023). <https://jme.bmj.com/content/early/2023/09/14/jme-2023-109449.long>
3. **Saylor KW**, Roberts MC. Implementation science can do even more for translational ethics. *American Journal of Bioethics*. 20(4):83-5. (2020). <https://www.tandfonline.com/doi/full/10.1080/15265161.2020.1730511>
4. Shah SK, Miller FG, Darton TC, Duenas D, Emerson C, Fernandez Lynch H, Jamrozik E, Jecker NS, Kamuya D, Kapulu M, Kimmelman J, MacKay D, Memoli MJ, Murphy SC, Palacios R, Richie TL, Roestenberg M, Saxena A, **Saylor KW**, Selgelid MJ, Vaswani V, Rid A. Unnecessary hesitancy on human vaccine tests-Response. *Science*. 359(6500). (2020). <https://www.science.org/doi/10.1126/science.abc9380>
5. **Saylor KW**. Multiple approaches to understanding and preventing elder abuse: Introduction to the cross-disciplinary National Institutes of Health workshop. *Journal of Elder Abuse and Neglect*. 28(4-5):179-84. (2016). <https://www.tandfonline.com/doi/full/10.1080/08946566.2016.1235998>
6. Bayefsky MJ, **Saylor KW**, Berkman BE. Parental consent for the use of residual newborn screening bloodspots: respecting individual liberty vs. ensuring public health. *JAMA*. 314(1):21-2. (2015). <https://jamanetwork.com/journals/jama/article-abstract/2319566>

RESEARCH IN PROGRESS

Under review

1. Gidwani R, **Saylor KW**, Russell L. Health state utility values: the implications of patient versus community ratings for assessing the value of care.

Working papers

2. **Saylor KW**, MacKay D. Bridging the gap between fairness-based theories of allocation and cost-utility analysis methods.
3. **Saylor KW**, Berg JS, Hassmiller Lich K. Cost-utility analysis of universal genetic screening for HBOC.
4. **Saylor KW**, Berg JS, Hassmiller Lich K. Equity-informed cost-utility analysis for universal genetic screening for HBOC.
5. **Saylor KW**, Johnson K, Alder IE, Berg JS, Hassmiller Lich K. Systematic review of economic evaluations of genetic testing: methodological critique and evidence assessment.

Active research projects

1. **Saylor KW**, Guerra C, Russell L, Domchek S, Joffe S, Kim D. Cost-effectiveness analysis of HBOC testing in high-risk, low-income, uninsured women to inform the National Breast and Cervical Cancer Early Detection Program. (Stage: model building using R and refining data)

CONFERENCE PRESENTATIONS

Participant

- 2023 The World Health Organization (WHO) Global Forum on Bioethics in Research. Forum topic: Ethics of health research priority setting. Montreux, Switzerland.

Workshop leader, moderator, or discussant

- 2025 Invited discussant for “Modelling the impacts of different conceptions of justice on population health outcomes” by Maxwell Smith, as part of the Invited Symposium “Population health ethics: Measuring and modelling injustice”. American Philosophical Association, Pacific Division, San Francisco, California.
- 2023 “Precision public health outcomes consensus building,” workshop planning committee, presenter, and workshop leader. “Learning from the experts,” panel moderator. Transdisciplinary Conference for Future Leaders in Precision Public Health, virtual meeting.

- 2023 “Ethical considerations and strategies for launching, evaluating, and improving population genetic screening programs,” designed and led a series of three moderated panels with Kimberly Foss, MS CGC. ELSI Conversations via ELSIhub, virtual sessions.
- 2022 “Networking session: Ethical Topics Associated with Population Genomic Screening,” Co-led with Kimberly Foss, MS CGC. ELSI Congress, virtual meeting.

Presentations

- 2023 “Health state utility values: the implications of patient versus non-patient ratings for assessing the value of care,” American Society for Bioethics and Humanities, Baltimore, MD.
- 2023 Panelist: “Trial Prioritization as a Bioethics Issue,” American Society for Bioethics and Humanities, Baltimore, MD.
- 2023 “Predictive genetic screening for hereditary breast and ovarian cancer (HBOC): Cost-effectiveness, values, and health equity,” CEER meeting, virtual meeting.
- 2022 “Using cost-utility analysis to evaluate the health equity impacts of population genetic screening for BRCA1/BRCA2,” ELSI Congress, virtual meeting.
- 2021 “Fairness-informed cost utility analysis of population genetic screening,” American Society for Bioethics and Humanities, virtual meeting.
- 2021 “Translational value and oversight of biomedical research using live vertebrate animals: A survey of US researchers,” American Society for Bioethics and Humanities, virtual meeting.
- 2020 “Who is and isn’t getting indicated testing? Clinical and demographic factors associated with HBOC testing in ovarian cancer patients,” ELSI Congress, New York, NY. *Abstract selected but canceled – COVID-19.*
- 2019 “Four Faces of Fair Subject Selection,” American Society for Bioethics and Humanities, Pittsburgh, PA.
- 2018 “Managing Uncertainty: The Potential and Limitations of Quantitative Modeling to Inform Clinical Integration of Genomics,” American Society for Bioethics and Humanities, Anaheim, CA.

Posters

- 2023 “Health state utility values: the implications of patient versus non-patient ratings for assessing the value of care,” Society for Medical Decision Making, Philadelphia, PA.
- 2022 “Variation across oncologists, distance to tertiary care hospital, and insurance type are factors in timely germline testing for ovarian cancer patients,” AGBT Precision Health meeting, San Diego, CA.
- 2022 “Potential for social value as a criterion for genomics research priority setting: moving from implicit to systematic evaluation,” NHGRI trainees meeting, Durham, NC.

- 2020 “Economic evaluations of predictive genetic screening: A systematic review of quality and findings,” American Society for Human Genetics and Genomics, virtual meeting.
- 2020 “What’s right and what’s wrong with economic evaluations of genetic screening: A systematic review and response,” ELSI Congress, New York, NY. *Abstract selected but canceled – COVID-19.*
- 2018 “Attitudes towards genetics among participants in the Jackson and Framingham Heart Studies,” American Society for Human Genetics and Genomics, San Diego, CA.
- 2017 “Biobank formalization and biospecimen ownership in U.S. biobanks,” ELSI Congress, Farmington, CT.

INVITED LECTURES AND CAMPUS TALKS

- 2024 “Health state utility values: the implications of patient versus non-patient ratings for assessing the value of care,” Program On Regulation, Therapeutics, And Law (PORTAL), Harvard Medical School.
- 2024 “The value of prediction: Modeling cost-effectiveness and health equity for genetic screening,” Center for Bioethics and Humanities, University of Colorado Anschutz Medical Campus.
- 2024 “The value of prediction: Modeling cost-effectiveness and health equity for genetic screening,” Geisinger.
- 2023 “The value of prediction: Modeling cost-effectiveness and health equity for genetic screening,” The Hastings Center.
- 2022 “Fairness-informed Cost Utility Analysis” Ethics and Epidemiology Workshop, University of Toronto.
- 2021 “Fairness-informed cost utility analysis of population genetic screening,” Penn Bioethics Seminar Series, University of Pennsylvania.
- 2020 “Beyond Maximizing Total Benefits: Ethics, Fairness, and Cost-effectiveness Analysis,” Royster Society of Fellows Research Seminar, UNC.
- 2019 “The Deceptive Border Between Research and Practice,” Royster Global Conference on Borders, UNC.
- 2017 “Federal Science Policy and Funding,” Cardiovascular Epidemiology Workshop, UNC.

GRANTS AND FUNDED FELLOWSHIPS

- 2022-2024 University of Pennsylvania T32 Postdoctoral Fellowship in Ethical, Legal and Social Implications of Genetics and Genomics
- 2022 Brocher Foundation Residency and Junior Researcher Scholarship (July-August)
- 2019-2020 Co-PI. North Carolina Translational and Clinical Sciences Institute \$2K Grant “Identifying undiagnosed genetic disease in the UNC Healthcare system”

2016-2021 National Science Foundation Graduate Research Fellowship (NSF-GRFP)
2016-2021 Royster Society of Fellows, UNC
2006-2009 Achievement Rewards for College Scientists (ARCS) Scholar, OHSU

AWARDS AND HONORS

2020 ELSI Congress 2020 Travel Award
2019 Hammer Fund recipient for conference travel, UNC
2016 Director's Award, National Institute on Aging
2015 Office of the Director Honor Award, National Institutes of Health
2014 GREAT Award, National Human Genome Research Institute
2013 Director's Award, National Institutes of Health
2011 Group Merit Award, National Institutes of Health
2011 Award for Special Projects, National Institutes of Health
2010 The Outstanding Master's Thesis Award, Oregon Health & Sciences University
2005 Award for promise in fields related to medicine, Macalester College

HONORARY AFFILIATIONS

2022-present Associate Fellow, Leonard Davis Institute of Health Economics
2019-2021 Parr Center for Ethics Graduate Fellow, UNC
2019-2021 Philosophy, Politics, and Economics Graduate Fellow, UNC
2019-2020 Teaching Fellow, UNC
2016-2018 Trainee, Center for Genomics and Society, UNC

RESEARCH SKILLS

- Quantitative analysis using Stata (e.g., multivariable regression analysis)
- Cost-utility analysis in Excel (including tree diagrams, Markov state transition models, probabilistic sensitivity analysis), novice-level cost-utility analysis in R
- Quasi-experimental/natural experiment research design (e.g., difference in difference, interrupted time series, regression discontinuity)
- Systematic review management in Covidence
- Regular use of reference managers (e.g., Zotero, EndNote, Mendelay) and MS Office

TEACHING

Instructor of record and course co-developer

Undergraduate students:

“Science and Society: The Hidden Forces that Drive Scientific Inquiry” (interdisciplinary undergraduate seminar). University of North Carolina. Fall 2019.

Invited lectures

High school students:

- 2023 “Gene drive policy and deliberative democracy”, Workshop for high schoolers’ Summer Internship Program, University of Pennsylvania.
- 2022 “Gene drive policy and deliberative democracy” (co-designed with Naomi Scheinerman, Ph.D.), Workshop for high schoolers’ Summer Internship Program, University of Pennsylvania.

Undergraduate students:

- 2023 “Genetic testing and health policy: Cost-effectiveness, values, and health equity”, Undergraduate summer research program, NHGRI Diversity Action Plan, University of Pennsylvania.
- 2013 “Ethical, Legal and Social Implications of Genomics Research,” Topics in Genomics, University of the District of Columbia, Washington, DC.
- 2008 “Morphology and Function of the Hair Cell Bundle,” Topics in Neuroscience, University of Portland, OR.

Medical students:

- 2023 Small group facilitator/discussion leader for University of Pennsylvania final year Ethics and Professionalism Medical Students. (20 hours of teaching).
- 2019 “The Ethics of Human Subjects Research,” Social and Health Systems for Medical Students, UNC.

Master’s and Ph.D. students:

- 2024 “Genetics and Research,” Bioethics and Policy: Genetics and Ethics, University of Pennsylvania.
- 2022 “Fairness-informed Cost Utility Analysis,” Techniques for the Economic Evaluation of Health Care, Department of Health Policy and Management, UNC.
- 2022 “Genetics and Research,” Bioethics and Policy: Genetics and Ethics, University of Pennsylvania.
- 2021 “Fairness-informed Cost Utility Analysis,” Techniques for the Economic Evaluation of Health Care, Department of Health Policy and Management, UNC.
- 2020 “Beyond Maximizing Total Benefits: Ethics, Fairness, and Cost-effectiveness Analysis,” Techniques for the Economic Evaluation of Health Care, Department of Health Policy and Management, UNC.

2015 “Research Ethics and Policy,” Health Policy and Management class, National Institutes of Health, Bethesda, MD.

Teacher training

2019 Teaching Summer Institute, University of North Carolina. 40 hours, focus on active, student-centric pedagogy.

Courses prepared to teach

- Normative Issues in Public Policy
- Politics and Public Policy
- Research Design
- Justice in Healthcare Allocation
- Equity and Economic Evaluation of Healthcare
- Introduction to Bioethics
- Science and Society
- Ethical, Legal, and Social Implications of Genomics
- Ethical Issues in Research

PROFESSIONAL SOCIETY MEMBERSHIP

2023-present Society for Medical Decision Making (SMDM)
2023-present The Professional Society for Health Economics and Outcomes Research (ISPOR)
2016-present American Society for Bioethics and Humanities (ASBH)
2018-2020 American Society for Human Genetics and Genomics (ASHG)

SERVICE TO PROFESSION AND INSTITUTION

Institutional Review Board

University of Pennsylvania Human Research Protections Program, 2023-2024.

Journal peer review

BMC Biomedical Ethics; Bioethics; Frontiers in Genetics; Frontiers in Health Services; Frontiers in Molecular Biosciences; Genetics in Medicine; Journal of Medical Ethics; Molecular Genetics & Genomic Medicine; Psychology and Health; Public Health Genomics

Conference abstract review

American Society for Bioethics and Humanities

Fellowship application pre-submission peer review and advising

UNC Graduate School

REFERENCES

Steven Joffe, M.D., M.P.H.
Chair of the Department of Medical Ethics & Health Policy
Chief of the Division of Medical Ethics
University of Pennsylvania
Joffes@upenn.edu
(215) 898-7136

Douglas MacKay, Ph.D.
Associate Professor of Public Policy
University of North Carolina
dmackay@email.unc.edu
(919) 962-1600

Megan Roberts, Ph.D.
Assistant Professor of Pharmacy
Director of Implementation Science in Precision Health and Society
University of North Carolina
megan.roberts@unc.edu
(919) 843-4071

Louise B. Russell, Ph.D.
Distinguished Professor Emeritus at Rutgers University
Adjunct Professor of Medical Ethics and Health Policy
University of Pennsylvania
louisebrussell1983@gmail.com